S91 Liver function tests during tuberculosis treatment and the implications on monitoring for hepatotoxicity. (15th November 2016)

• Record Type: Journal Article
• Authors: Tweed, CD; Wills, G; Crook, AM; Meredith, SK; Nunn, AJ; Mendel, CM; Murray, SR; McHugh, TD; Gillespie, SH
• Is Part Of: Thorax. Volume 71(2016)Supplement 3
• Page Start: A52
• Page End: A53
• Publication Date: 2016-11-15
• Subjects: Chest -- Diseases -- Periodicals; Thorax; Chest -- Diseases; Periodicals; Periodicals; 617.54
• DOI: 10.1136/thoraxjnl-2016-209333.97
• Languages: English
• ISSNs: 0040-6376

Abstract

Abstract : Introduction and objectives: Drug-induced hepatotoxicity is a common complication of tuberculosis treatment. 1 Guidelines based on expert opinion are available, but the natural history of liver enzyme measurements over the course of treatment and the most effective approach to monitoring on treatment remains unclear. We investigated the pattern of liver enzyme levels in the REMoxTB trial to describe the magnitude and timing of elevations, along with factors that could influence enzyme patterns, and related this to liver function monitoring. Methods: Patients received either standard tuberculosis treatment (2EHRZ/4HR), or a four-month regimen with moxifloxacin substituted for ethambutol (isoniazid arm, 2MHRZ/2MHR) or isoniazid (ethambutol arm, 2EMRZ/2MR). Liver function tests were performed at weeks 0, 2, 4, 8, 12, 17, and during adverse events. The Chi Square or Fisher's exact test was used for testing proportions among groups, log rank test for comparison of time, and Students t test for comparison of means. Results: 639 patients were allocated to receive standard therapy as controls, 654 to the isoniazid arm, and 635 to the ethambutol arm (see Table 1 ). 60 patients (9.4%) taking standard therapy developed a peak ALT/AST ≥ 3 × ULN at median time 28 days (IQR 14–56). The mean difference in time to reach peak ALT was 7 days between isoniazid-containing regimens and the ethambutol arm, and a higher proportion of Asian patients elevated ALT/AST ≥ 3 × ULN in isoniazid-containing arms (51.0% vs 26.3%, (p < 0.001)). Of the 40/421 (9.5%) HIV positive in Africa, 24/421 elevated ALT/AST ≥ 3 × ULN compared to 25/121 (5.7% vs 20.7%, (p < 0.001)) in India elevating ALT/AST ≥ 3 × ULN where 2/121 (1.7%) were HIV-positive. Discussion: Monitoring liver function routinely for the first two months of HRZE therapy would have detected approximately 75% of patients with a peak enzyme elevation of ≥3 × ULN, and we would recommend this as a standard of care based on these results. However, there is reassurance that over 90% of patients completed therapy without an ALT/AST result ≥3 xULN. HIV positive and Asian patients were at higher risk of liver enzyme elevation and there was a shorter time to peak ALT/AST for those receiving isoniazid. Reference: Thompson N, Caplin M, Hamilton M, et al . Anti-tuberculosis medication and the liver: dangers and recommendations in management. Eur Respir J 1995;8 :1384–1388.